Department of Biochemistry, University of Turku, Turku, Finland.
Curr Opin Infect Dis. 2010 Jun;23(3):268-74. doi: 10.1097/QCO.0b013e32833939b0.
Several studies show that the number of FcgammaRI (CD64) on the surface of neutrophils increases in infections. However, in spite of increased research interest in recent years, there is no clear general view on the usability of neutrophil FcgammaRI in clinical infection diagnostics. This review tries to bring the clarity to this matter.
It is shown here that although the high number of FcgammaRI on neutrophils is a sensitive marker of bacterial infection, it is highly expressed also in DNA virus infections. As a consequence, neutrophil FcgammaRI cannot be used in distinguishing between bacterial and viral infections. It is also clear that FcgammaRI on neutrophils cannot be used in distinguishing between Gram-positive and Gram-negative bacterial infections or between microbiologically confirmed and clinically diagnosed bacterial infections. In addition, neutrophil FcgammaRI cannot be used to reliably detect RNA virus infections, inflammatory diseases, or cancer.
The best clinical benefit from the quantitative analysis of FcgammaRI on neutrophils will be obtained when it is used simultaneously with a reliable bacterial infection marker. DNA virus score point is an efficient novel method in differentiating between DNA and RNA virus infections.
多项研究表明，中性粒细胞表面 FcγRⅠ（CD64）的数量在感染中增加。然而，尽管近年来研究兴趣增加，但中性粒细胞 FcγRⅠ在临床感染诊断中的可用性仍没有明确的普遍观点。本综述试图澄清这一问题。
这里表明，虽然中性粒细胞上大量的 FcγRⅠ是细菌感染的敏感标志物，但它也在 DNA 病毒感染中高度表达。因此，中性粒细胞 FcγRⅠ不能用于区分细菌和病毒感染。同样清楚的是，中性粒细胞 FcγRⅠ不能用于区分革兰氏阳性和革兰氏阴性细菌感染，也不能用于区分微生物学证实和临床诊断的细菌感染。此外，中性粒细胞 FcγRⅠ不能用于可靠地检测 RNA 病毒感染、炎症性疾病或癌症。
将中性粒细胞 FcγRⅠ的定量分析与可靠的细菌感染标志物同时使用，将获得最佳的临床获益。DNA 病毒评分是区分 DNA 和 RNA 病毒感染的一种有效新方法。
